362 related articles for article (PubMed ID: 35347134)
1. Single-cell transcriptomic analysis suggests two molecularly subtypes of intrahepatic cholangiocarcinoma.
Song G; Shi Y; Meng L; Ma J; Huang S; Zhang J; Wu Y; Li J; Lin Y; Yang S; Rao D; Cheng Y; Lin J; Ji S; Liu Y; Jiang S; Wang X; Zhang S; Ke A; Wang X; Cao Y; Ji Y; Zhou J; Fan J; Zhang X; Xi R; Gao Q
Nat Commun; 2022 Mar; 13(1):1642. PubMed ID: 35347134
[TBL] [Abstract][Full Text] [Related]
2. Novel cell subtypes of SPP1 + S100P+, MS4A1-SPP1 + S100P+ were key subpopulations in intrahepatic cholangiocarcinoma.
Xuan Z; Liu L; Zhang G; Zheng X; Jiang J; Wang K; Huang P
Biochim Biophys Acta Gen Subj; 2023 Sep; 1867(9):130420. PubMed ID: 37433400
[TBL] [Abstract][Full Text] [Related]
3. Revealing the role of necroptosis microenvironment: FCGBP + tumor-associated macrophages drive primary liver cancer differentiation towards cHCC-CCA or iCCA.
Wang C; Chen C; Hu W; Tao L; Chen J
Apoptosis; 2024 Apr; 29(3-4):460-481. PubMed ID: 38017206
[TBL] [Abstract][Full Text] [Related]
4. An immunostaining panel of C-reactive protein, N-cadherin, and S100 calcium binding protein P is useful for intrahepatic cholangiocarcinoma subtyping.
Akita M; Sawada R; Komatsu M; Suleman N; Itoh T; Ajiki T; Heaton N; Fukumoto T; Zen Y
Hum Pathol; 2021 Mar; 109():45-52. PubMed ID: 33321161
[TBL] [Abstract][Full Text] [Related]
5. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.
Rhee H; Ko JE; Chung T; Jee BA; Kwon SM; Nahm JH; Seok JY; Yoo JE; Choi JS; Thorgeirsson SS; Andersen JB; Lee HS; Woo HG; Park YN
Liver Int; 2018 Jan; 38(1):113-124. PubMed ID: 28608943
[TBL] [Abstract][Full Text] [Related]
7. Correlation of Vein-Rich Tumor Microenvironment of Intrahepatic Cholangiocarcinoma With Tertiary Lymphoid Structures and Patient Outcome.
Doi N; Ino Y; Fuse M; Esaki M; Shimada K; Hiraoka N
Mod Pathol; 2024 Feb; 37(2):100401. PubMed ID: 38043787
[TBL] [Abstract][Full Text] [Related]
8. Immunosuppressive role of SPP1-CD44 in the tumor microenvironment of intrahepatic cholangiocarcinoma assessed by single-cell RNA sequencing.
Cheng M; Liang G; Yin Z; Lin X; Sun Q; Liu Y
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5497-5512. PubMed ID: 36469154
[TBL] [Abstract][Full Text] [Related]
9. Multiomics analysis reveals metabolic subtypes and identifies diacylglycerol kinase α (DGKA) as a potential therapeutic target for intrahepatic cholangiocarcinoma.
Liu W; Wang H; Zhao Q; Tao C; Qu W; Hou Y; Huang R; Sun Z; Zhu G; Jiang X; Fang Y; Gao J; Wu X; Yang Z; Ping R; Chen J; Yang R; Chu T; Zhou J; Fan J; Tang Z; Yang D; Shi Y
Cancer Commun (Lond); 2024 Feb; 44(2):226-250. PubMed ID: 38143235
[TBL] [Abstract][Full Text] [Related]
10. Intrahepatic cholangiocarcinoma: typical features, uncommon variants, and controversial related entities.
Zen Y
Hum Pathol; 2023 Feb; 132():197-207. PubMed ID: 35697170
[TBL] [Abstract][Full Text] [Related]
11. Activation of Fas/FasL pathway and the role of c-FLIP in primary culture of human cholangiocarcinoma cells.
Carnevale G; Carpino G; Cardinale V; Pisciotta A; Riccio M; Bertoni L; Gibellini L; De Biasi S; Nevi L; Costantini D; Overi D; Cossarizza A; de Pol A; Gaudio E; Alvaro D
Sci Rep; 2017 Oct; 7(1):14419. PubMed ID: 29089545
[TBL] [Abstract][Full Text] [Related]
12. S100P immunostaining identifies a subset of peripheral-type intrahepatic cholangiocarcinomas with morphological and molecular features similar to those of perihilar and extrahepatic cholangiocarcinomas.
Tsai JH; Huang WC; Kuo KT; Yuan RH; Chen YL; Jeng YM
Histopathology; 2012 Dec; 61(6):1106-16. PubMed ID: 22882148
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of small duct- and large duct-type intrahepatic cholangiocarcinoma.
Kinzler MN; Schulze F; Jeroch J; Schmitt C; Ebner S; Gretser S; Bein J; Finkelmeier F; Trojan J; Zeuzem S; Schnitzbauer AA; Demes MC; Reis H; Wild PJ; Walter D
Histopathology; 2024 May; 84(6):1061-1067. PubMed ID: 38409827
[TBL] [Abstract][Full Text] [Related]
14. Dense GM-CSFR
Saranaruk P; Waraasawapati S; Chamgramol Y; Sawanyawisuth K; Paungpan N; Somphud N; Wongkham C; Okada S; Wongkham S; Vaeteewoottacharn K
PeerJ; 2023; 11():e14883. PubMed ID: 36883059
[TBL] [Abstract][Full Text] [Related]
15. Identification and validation of a lactate metabolism-related six-gene prognostic signature in intrahepatic cholangiocarcinoma.
Sang C; Yan L; Lin J; Lin Y; Gao Q; Shen X
J Cancer Res Clin Oncol; 2024 Apr; 150(4):199. PubMed ID: 38627278
[TBL] [Abstract][Full Text] [Related]
16. Different roles of S100P overexpression in intrahepatic cholangiocarcinoma: carcinogenesis of perihilar type and aggressive behavior of peripheral type.
Aishima S; Fujita N; Mano Y; Kubo Y; Tanaka Y; Taketomi A; Shirabe K; Maehara Y; Oda Y
Am J Surg Pathol; 2011 Apr; 35(4):590-8. PubMed ID: 21412073
[TBL] [Abstract][Full Text] [Related]
17. Geospatial Immune Heterogeneity Reflects the Diverse Tumor-Immune Interactions in Intrahepatic Cholangiocarcinoma.
Lin Y; Peng L; Dong L; Liu D; Ma J; Lin J; Chen X; Lin P; Song G; Zhang M; Liu Y; Rao J; Wei C; Lu Y; Zhang S; Ding G; Peng Z; Lu H; Wang X; Zhou J; Fan J; Wu K; Gao Q
Cancer Discov; 2022 Oct; 12(10):2350-2371. PubMed ID: 35853232
[TBL] [Abstract][Full Text] [Related]
18. MYC determines lineage commitment in KRAS-driven primary liver cancer development.
D'Artista L; Moschopoulou AA; Barozzi I; Craig AJ; Seehawer M; Herrmann L; Minnich M; Kang TW; Rist E; Henning M; Klotz S; Heinzmann F; Harbig J; Sipos B; Longerich T; Eilers M; Dauch D; Zuber J; Wang XW; Zender L
J Hepatol; 2023 Jul; 79(1):141-149. PubMed ID: 36906109
[TBL] [Abstract][Full Text] [Related]
19. Role of immunophenotypic characterisation in prognostic subtyping of intrahepatic cholangiocarcinoma.
Li Z; Huang N; Du Q; Huang W; Wang B; Wang B; Shen G; Zhang H; Shi S; Wang L
Pathology; 2023 Dec; 55(7):979-988. PubMed ID: 37858435
[TBL] [Abstract][Full Text] [Related]
20. Single-cell Transcriptomic Architecture Unraveling the Complexity of Tumor Heterogeneity in Distal Cholangiocarcinoma.
Li H; Qu L; Yang Y; Zhang H; Li X; Zhang X
Cell Mol Gastroenterol Hepatol; 2022; 13(5):1592-1609.e9. PubMed ID: 35219893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]